Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Tirzepatide (development code LY3298176) is a single engineered peptide a fatty-acid-modified 39-amino-acid molecule that acts as a dual agonist at two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
Preclinical studies have indicated that GLP1RAs, such as tirzepatide, may directly impact the vasculature by enhancing endothelial function and decreasing inflammation, which are important in preventing atherosclerosis[30]
The public health burden of obesity has increased worldwide
-1775582746855.png&w=3840&q=75)
Some patients notice subjective differences between formulations, but these typically resolve within one to two weeks
For many patients, thats meaningful particularly early in treatment when theyre still determining whether GLP-1 therapy will work for them
US$ 28.77
US$ 25.15
US$ 24.48
%20(1).png)
US$ 29.55
US$ 22.63
US$ 29.75
US$ 20.89
